Quick Answer
Syndax Pharmaceuticals Inc reported Net Income Loss of -$285.42 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +10.5% in Net Income Loss from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Syndax Pharmaceuticals Inc's Net Income Loss has declined by 1,339.5%.
- Historical annual values: Fiscal year 2025: -$285.42 million | Fiscal year 2024: -$318.76 million | Fiscal year 2023: -$209.36 million | Fiscal year 2022: -$149.34 million | Fiscal year 2021: $24.93 million | Fiscal year 2020: -$73.16 million | Fiscal year 2019: -$56.05 million | Fiscal year 2018: -$73.96 million | Fiscal year 2017: -$60.80 million | Fiscal year 2016: -$44.47 million | Fiscal year 2015: -$24.12 million | Fiscal year 2014: -$19.83 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: